Cardiol Therapeutics Inc.
NASDAQ:CRDLDrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $114.64M
- Beta
- 0.80
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.31M
Average 0.68M
CRDL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Cardiol Therapeutics Inc.NASDAQ: CRDL
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of CA$4.96M rose 32.1% year over year, ahead of the +22.5% change in trailing-twelve-month research & development. Sequentially, it rose 80.9% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +32.1% holds above the trailing-twelve-month pace of +22.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CAD · from the income statement
- Latest · FY2025
- 14.02M CAD
- Year-over-year change
- +0.0%
- 4-year CAGR
- +13.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.02M | +0.0% |
| FY2024 | 2024-12-31 | 14.01M | +30.6% |
| FY2023 | 2023-12-31 | 10.73M | -23.3% |
| FY2022 | 2022-12-31 | 13.99M | +62.8% |
| FY2021 | 2021-12-31 | 8.59M | — |
Research & Development vs competitors
How CRDL compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +22.5% is the 3rd highest of 10, against a peer median of -11.4%.
- Over three fiscal years its annual growth of +0.1% compares with a peer median of -13.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $37.8M USD | +29.2% | -26.9% | 59059.4% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $32.3M USD | -29.1% | +37.8% | — |
IMAImageneBio Inc | LTM Mar 2026 | $30.77M USD | +23.4% | -23.7% | — |
| LTM Mar 2026 | €22.87M EUR | -34.8% | -11.8% | 77989.1% | |
| LTM Mar 2026 | $18.17M USD | +11.9% | +8.6% | — | |
| LTM Mar 2026 | $16.26M USD | -26.0% | -14.7% | 106.1% | |
| LTM Mar 2026 | CA$15.22M CAD | +22.5% | +0.1% | — | |
| LTM Mar 2026 | $6.11M USD | -11.4% | -6.7% | 5814.3% | |
| LTM Mar 2026 | $1.71M USD | -51.6% | — | 1.7% | |
| LTM Jun 2025 | ₪386K ILS | +10.0% | -14.9% | 0.2% | |
| Peer median (excluding CRDL) | — | -11.4% | -13.3% | 2960.2% | |
Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 62.27K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 174.26K | 162.23K | 187.38K | 0 | 0 |
| Gross Profit | (112K) | (162.23K) | (187.38K) | 0 | 0 |
| Gross Margin | -179.9% | — | — | — | — |
| Research & Development | 8.59M | 13.99M | 10.73M | 14.01M | 14.02M |
| Selling, General & Admin | 21.86M | 16.34M | 11.55M | 25.89M | 20.2M |
| Operating Expenses | 30.46M | 30.33M | 22.29M | 40.28M | 34.32M |
| Depreciation & Amortization | 174.26K | 162.23K | 187.38K | 162.11K | 101.98K |
| EBITDA | (24.84M) | (22.66M) | (21.04M) | (36.52M) | (33.72M) |
| EBITDA Margin | -39891.0% | — | — | — | — |
| Operating Income | (30.57M) | (30.49M) | (22.47M) | (40.28M) | (34.32M) |
| Operating Margin | -49092.4% | — | — | — | — |
| Interest Income | 106K | 1.24M | 2.04M | 1.19M | 726.4K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.56M | 7.68M | 1.25M | 3.6M | 497.42K |
| Income Before Tax | (25.01M) | (22.82M) | (21.22M) | (36.68M) | (33.82M) |
| Pre-Tax Margin | -40170.9% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (25.01M) | (22.82M) | (21.22M) | (36.68M) | (33.82M) |
| Net Margin | -40170.9% | — | — | — | — |
| EPS (Basic) | (0.73) | (0.49) | (0.44) | (0.51) | (0.39) |
| EPS (Diluted) | (0.73) | (0.49) | (0.44) | (0.51) | (0.39) |
| Weighted Avg Shares | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
| Weighted Avg Shares (Diluted) | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
Cardiol Therapeutics Inc.
NASDAQ:CRDL
Intrinsic Alpha fair value
Locked
Current Price
$0.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.